Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
In Guru Portfolios
Portfolio Weight (%)
Change
Fund
Portfolio Weight (%)
Change
Fund
Portfolio Weight (%)
Change
Fund
Manager | Fund | Portfolio Weight (%) | Change |
|---|---|---|---|
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
Data is available to registered users only | Data is available to registered users only | Data is available to registered users only | Data is available to registered users only |
About
SelectQuote, Inc. operates as a tech-driven, direct-to-consumer marketplace, offering a wide spectrum of insurance products to individuals throughout the United States. These policies are underwritten by a variety of insurance carriers. The company structures its operations across three core divisions: Senior, Life, and Auto & Home. Within its Senior segment, SelectQuote provides access to a comprehensive suite of health policies, including Medicare Advantage, Medicare Supplement, and Medicare Part D plans. This segment also features ancillary coverages such as prescription drug plans, dental, vision, and hearing benefits. The Life division concentrates on term life insurance offerings, while the Auto & Home segment delivers personal automobile, homeowners', and general casualty insurance solutions. Established in 1999, SelectQuote, Inc. is headquartered in Overland Park, Kansas.
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITD.
Target Price
The average target price of SLQT is 3.1 and suggests 228% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa